Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 465

1.

Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations.

Panzuto F, Puscedddu S, Faggiano A, Rinzivillo M, Brighi N, Prinzi N, Riccardi F, Iannicelli E, Maggio I, Femia D, Tafuto S, Manuzzi L, Di Sarno A, Annibale B, de Braud F, Campana D; Itanet (Italian Association for Neuroendocrine Tumours).

Pancreatology. 2019 Sep 30. pii: S1424-3903(19)30736-7. doi: 10.1016/j.pan.2019.09.015. [Epub ahead of print]

PMID:
31587962
2.

Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer.

Giaccherini C, Marchetti M, Masci G, Verzeroli C, Russo L, Celio L, Sarmiento R, Gamba S, Tartari CJ, Diani E, Vignoli A, Malighetti P, Spinelli D, Tondini C, Barni S, Giuliani F, Petrelli F, D'Alessio A, Gasparini G, De Braud F, Santoro A, Labianca R, Falanga A.

Haematologica. 2019 Sep 26. pii: haematol.2019.228981. doi: 10.3324/haematol.2019.228981. [Epub ahead of print]

3.

Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study.

Procopio G, Apollonio G, Cognetti F, Miceli R, Milella M, Mosca A, Chiuri VE, Bearz A, Morelli F, Ortega C, Atzori F, Donini M, Ratta R, Raimondi A, Claps M, Martinetti A, Capitanio U, de Braud FG, Cappelletti V, Verzoni E.

Eur Urol Oncol. 2019 Sep 18. pii: S2588-9311(19)30137-3. doi: 10.1016/j.euo.2019.08.011. [Epub ahead of print]

PMID:
31542243
4.

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.

Morano F, Corallo S, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Murialdo R, Zaniboni A, Sartore-Bianchi A, Tomasello G, Racca P, Clavarezza M, Adamo V, Perrone F, Gloghini A, Tamborini E, Busico A, Martinetti A, Palermo F, Loupakis F, Milione M, Fucà G, Di Bartolomeo M, de Braud F, Pietrantonio F.

J Clin Oncol. 2019 Sep 20:JCO1901254. doi: 10.1200/JCO.19.01254. [Epub ahead of print]

PMID:
31539295
5.

Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.

Galli G, De Toma A, Pagani F, Randon G, Trevisan B, Prelaj A, Ferrara R, Proto C, Signorelli D, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G.

Lung Cancer. 2019 Sep 10;137:38-42. doi: 10.1016/j.lungcan.2019.08.030. [Epub ahead of print]

PMID:
31526910
6.

Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study.

Fucà G, Mariani L, Lo Vullo S, Galli G, Berardi R, Di Nicola M, Vernieri C, Morelli D, Dotti K, Fiordoliva I, Rinaldi S, Gavazzi C, Pietrantonio F, Platania M, de Braud F.

Sci Rep. 2019 Sep 10;9(1):12993. doi: 10.1038/s41598-019-49601-3.

7.

Collecting ducts carcinoma: An orphan disease. Literature overview and future perspectives.

Pagani F, Colecchia M, Sepe P, Apollonio G, Claps M, Verzoni E, de Braud F, Procopio G.

Cancer Treat Rev. 2019 Sep;79:101891. doi: 10.1016/j.ctrv.2019.101891. Epub 2019 Aug 27. Review.

PMID:
31491662
8.

The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice.

Raimondi A, Randon G, Sepe P, Claps M, Verzoni E, de Braud F, Procopio G.

Int J Mol Sci. 2019 Aug 30;20(17). pii: E4263. doi: 10.3390/ijms20174263. Review.

9.

Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer.

Galli G, Proto C, Cossa M, Valeri B, Sdao S, Signorelli D, Imbimbo M, de Braud F, Garassino MC, Lo Russo G.

Tumori. 2019 Aug 28:300891619872546. doi: 10.1177/0300891619872546. [Epub ahead of print]

PMID:
31456503
10.

Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma.

Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, Randon G, De Braud F, Del Vecchio M.

Tumori. 2019 Aug 26:300891619868009. doi: 10.1177/0300891619868009. [Epub ahead of print]

PMID:
31446882
11.

Should we use combination therapy for all advanced renal cell carcinoma?

Procopio G, Sepe P, Claps M, de Braud F, Verzoni E.

Lancet Oncol. 2019 Oct;20(10):1331-1332. doi: 10.1016/S1470-2045(19)30518-2. Epub 2019 Aug 16. No abstract available.

PMID:
31427206
12.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalá M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ.

Ann Oncol. 2019 Aug 13. pii: mdz221. doi: 10.1093/annonc/mdz221. [Epub ahead of print] No abstract available.

PMID:
31406976
13.

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study.

Di Cosimo S, La Verde N, Moretti A, Cazzaniga ME, Generali D, Bianchi GV, Mariani L, Torri V, Crippa F, Paolini B, Scaperrotta G, De Santis MC, Di Nicola M, Apolone G, Gulino A, Tripodo C, Colombo MP, Folli S, de Braud F.

PLoS One. 2019 Aug 7;14(8):e0220644. doi: 10.1371/journal.pone.0220644. eCollection 2019.

14.

Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment.

Koschorke A, Faraci S, Giani D, Chiodoni C, Iorio E, Canese R, Colombo MP, Lamolinara A, Iezzi M, Ladomery M, Vernieri C, de Braud F, Di Nicola M, Tagliabue E, Castagnoli L, Pupa SM.

Cell Oncol (Dordr). 2019 Aug 2. doi: 10.1007/s13402-019-00464-w. [Epub ahead of print]

PMID:
31376137
15.

Axillary nodal involvement by primary tumor features in early breast cancer: an analysis of 2600 patients.

De Santis MC, La Rocca E, Meneghini E, Bregni G, Di Lorenzo G, Galli G, Di Nicola M, Folli S, Gennaro M, Pruneri G, Paolini B, Daidone MG, De Braud F, Apolone G, Sant M, Di Cosimo S.

Clin Transl Oncol. 2019 Aug 1. doi: 10.1007/s12094-019-02188-7. [Epub ahead of print]

PMID:
31372896
16.

Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy.

Galli G, Proto C, Signorelli D, Imbimbo M, Ferrara R, Prelaj A, De Toma A, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G.

Future Oncol. 2019 Aug;15(23):2743-2757. doi: 10.2217/fon-2019-0055. Epub 2019 Jul 24.

PMID:
31339060
17.

The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study.

Di Cosimo S, Triulzi T, Pizzamiglio S, De Cecco L, de Azambuja E, Fumagalli D, Putzai L, Harbeck N, Izquierdo M, Peña L, Daidone MG, Huober J, Gori S, Cinieri S, Torri V, Baselga J, Piccart M, de Braud FG, Apolone G, Verderio P, Tagliabue E.

Eur J Cancer. 2019 Sep;118:1-9. doi: 10.1016/j.ejca.2019.06.001. Epub 2019 Jul 5.

18.

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.

Pietrantonio F, Morano F, Corallo S, Miceli R, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Bergamo F, Sartore-Bianchi A, Tampellini M, Racca P, Clavarezza M, Berenato R, Caporale M, Antista M, Niger M, Smiroldo V, Murialdo R, Zaniboni A, Adamo V, Tomasello G, Giordano M, Petrelli F, Longarini R, Cinieri S, Falcone A, Zagonel V, Di Bartolomeo M, de Braud F.

JAMA Oncol. 2019 Jul 3. doi: 10.1001/jamaoncol.2019.1467. [Epub ahead of print]

19.

Artificial Intelligence Estimates the Importance of Baseline Factors in Predicting Response to Anti-PD1 in Metastatic Melanoma.

Indini A, Di Guardo L, Cimminiello C, De Braud F, Del Vecchio M.

Am J Clin Oncol. 2019 Aug;42(8):643-648. doi: 10.1097/COC.0000000000000566.

PMID:
31261257
20.

Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable.

Ongaro E, Cremolini C, Rossini D, Corti F, Pagani F, Morelli L, Urbani L, Masi G, Sposito C, Filippi B, Borelli B, Zucchelli G, Moretto R, Boccaccino A, Solaini L, de Braud F, Mazzaferro V, Falcone A, Cucchetti A, Pietrantonio F.

ESMO Open. 2019 May 9;4(2):e000496. doi: 10.1136/esmoopen-2019-000496. eCollection 2019.

21.

The role of metastasectomy in advanced renal cell carcinoma.

Apollonio G, Raimondi A, Verzoni E, Claps M, Sepe P, Pagani F, Ratta R, Montorsi F, De Braud FGM, Procopio G.

Expert Rev Anticancer Ther. 2019 Jul;19(7):603-611. doi: 10.1080/14737140.2019.1625772. Epub 2019 Jun 8.

PMID:
31159619
22.

Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.

Milione M, Miceli R, Barretta F, Pellegrinelli A, Spaggiari P, Tagliabue G, Centonze G, Paolino C, Mangogna A, Kankava K, Pusceddu S, Giacomelli L, Corti A, Cotsoglou C, Mazzaferro V, Sozzi G, de Braud F, Pruneri G, Anichini A.

J Pathol Clin Res. 2019 May 28. doi: 10.1002/cjp2.135. [Epub ahead of print]

23.

Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives.

Vernieri C, Milano M, Brambilla M, Mennitto A, Maggi C, Cona MS, Prisciandaro M, Fabbroni C, Celio L, Mariani G, Bianchi GV, Capri G, de Braud F.

Crit Rev Oncol Hematol. 2019 Jul;139:53-66. doi: 10.1016/j.critrevonc.2019.05.001. Epub 2019 May 3. Review.

PMID:
31112882
24.

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.

Sharma P, Siefker-Radtke A, de Braud F, Basso U, Calvo E, Bono P, Morse MA, Ascierto PA, Lopez-Martin J, Brossart P, Rohrberg K, Mellado B, Fischer BS, Meadows-Shropshire S, Abdel Saci, Callahan MK, Rosenberg J.

J Clin Oncol. 2019 Jul 1;37(19):1608-1616. doi: 10.1200/JCO.19.00538. Epub 2019 May 17. Erratum in: J Clin Oncol. 2019 Aug 10;37(23):2094.

PMID:
31100038
25.

Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer.

Galli G, Triulzi T, Proto C, Signorelli D, Imbimbo M, Poggi M, Fucà G, Ganzinelli M, Vitali M, Palmieri D, Tessari A, de Braud F, Garassino MC, Colombo MP, Lo Russo G.

Lung Cancer. 2019 Jun;132:72-78. doi: 10.1016/j.lungcan.2019.04.008. Epub 2019 Apr 8.

26.

Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial.

Platania M, Pasini F, Porcu L, Boeri M, Verderame F, Modena Y, Del Conte A, Nichetti F, Garassino MC, Martinetti A, Sottotetti E, Cavanna L, Vattemi E, Pozzessere D, Bertolini A, Irtelli L, Verri C, Sozzi G, Proto C, Pastorino U, Torri V, Fraccon AP, Spinnato F, Signorelli D, Lo Russo G, Tuzi A, Gallucci R, Cinieri S, Mencoboni M, Antonelli P, Giacomelli L, de Braud F.

Lung Cancer. 2019 Jun;132:17-23. doi: 10.1016/j.lungcan.2019.04.001. Epub 2019 Apr 3.

PMID:
31097088
27.

Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei.

Raimondi A, Corallo S, Niger M, Antista M, Randon G, Morano F, Milione M, Kusamura S, Baratti D, Guaglio M, Cremolini C, Marmorino F, Di Bartolomeo M, Deraco M, De Braud F, Pietrantonio F.

Clin Colorectal Cancer. 2019 Jun;18(2):e179-e190. doi: 10.1016/j.clcc.2019.03.002. Epub 2019 Apr 1.

PMID:
31023524
28.

Adjuvant radiotherapy for Merkel cell carcinoma: A systematic review and meta-analysis.

Petrelli F, Ghidini A, Torchio M, Prinzi N, Trevisan F, Dallera P, De Stefani A, Russo A, Vitali E, Bruschieri L, Costanzo A, Seghezzi S, Ghidini M, Varricchio A, Cabiddu M, Barni S, de Braud F, Pusceddu S.

Radiother Oncol. 2019 May;134:211-219. doi: 10.1016/j.radonc.2019.02.015. Epub 2019 Feb 28. Review.

PMID:
31005218
29.

Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.

Fucà G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, Ferrara R, Zilembo N, Ganzinelli M, Sica A, Torri V, Colombo MP, Vernieri C, Balsari A, de Braud F, Garassino MC, Signorelli D.

ESMO Open. 2019 Feb 27;4(1):e000457. doi: 10.1136/esmoopen-2018-000457. eCollection 2019.

30.

Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study.

Cremolini C, Benelli M, Fontana E, Pagani F, Rossini D, Fucà G, Busico A, Conca E, Di Donato S, Loupakis F, Schirripa M, Lonardi S, Borelli B, Ongaro E, Eason K, Morano F, Casagrande M, Fassan M, Sadanandam A, de Braud F, Falcone A, Pietrantonio F.

ESMO Open. 2019 Mar 8;4(2):e000489. doi: 10.1136/esmoopen-2019-000489. eCollection 2019.

31.

Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.

Pusceddu S, Ghidini M, Torchio M, Corti F, Tomasello G, Niger M, Prinzi N, Nichetti F, Coinu A, Di Bartolomeo M, Cabiddu M, Passalacqua R, de Braud F, Petrelli F.

Cancers (Basel). 2019 Apr 5;11(4). pii: E484. doi: 10.3390/cancers11040484. Review.

32.

Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component.

Moretto R, Morano F, Ongaro E, Rossini D, Pietrantonio F, Casagrande M, Antoniotti C, Corallo S, Marmorino F, Cortiula F, Nichetti F, Borelli B, Zucchelli G, Boccaccino A, Masi G, de Braud F, Falcone A, Cremolini C.

Clin Colorectal Cancer. 2019 Jun;18(2):116-124. doi: 10.1016/j.clcc.2019.02.007. Epub 2019 Mar 7.

PMID:
30952563
33.

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.

Di Bartolomeo M, Niger M, Morano F, Corallo S, Antista M, Tamberi S, Lonardi S, Di Donato S, Berardi R, Scartozzi M, Cardellino GG, Di Costanzo F, Rimassa L, Luporini AG, Longarini R, Zaniboni A, Bertolini A, Tomasello G, Pinotti G, Scagliotti G, Tortora G, Bonetti A, Spallanzani A, Frassineti GL, Tassinari D, Giuliani F, Cinieri S, Maiello E, Verusio C, Bracarda S, Catalano V, Basso M, Ciuffreda L, De Vita F, Parra HS, Fornaro L, Caporale M, de Braud F, Pietrantonio F.

BMC Cancer. 2019 Mar 29;19(1):283. doi: 10.1186/s12885-019-5498-3.

34.

The landscape of d16HER2 splice variant expression across HER2-positive cancers.

Volpi CC, Pietrantonio F, Gloghini A, Fucà G, Giordano S, Corso S, Pruneri G, Antista M, Cremolini C, Fasano E, Saggio S, Faraci S, Di Bartolomeo M, de Braud F, Di Nicola M, Tagliabue E, Pupa SM, Castagnoli L.

Sci Rep. 2019 Mar 5;9(1):3545. doi: 10.1038/s41598-019-40310-5.

35.

Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective Analysis.

Galli G, Cavalieri S, Di Guardo L, Cimminiello C, Nichetti F, Corti F, Garcia MA, Pappalardi B, Fallai C, de Braud F, Platania M, Del Vecchio M.

Oncol Res Treat. 2019;42(4):186-194. doi: 10.1159/000497211. Epub 2019 Mar 5.

36.

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.

Mehnert JM, Varga A, Brose MS, Aggarwal RR, Lin CC, Prawira A, de Braud F, Tamura K, Doi T, Piha-Paul SA, Gilbert J, Saraf S, Thanigaimani P, Cheng JD, Keam B.

BMC Cancer. 2019 Mar 4;19(1):196. doi: 10.1186/s12885-019-5380-3.

37.

Prognostic impact of ATM mutations in patients with metastatic colorectal cancer.

Randon G, Fucà G, Rossini D, Raimondi A, Pagani F, Perrone F, Tamborini E, Busico A, Peverelli G, Morano F, Niger M, Antista M, Corallo S, Saggio S, Borelli B, Zucchelli G, Milione M, Pruneri G, Di Bartolomeo M, Falcone A, de Braud F, Cremolini C, Pietrantonio F.

Sci Rep. 2019 Feb 27;9(1):2858. doi: 10.1038/s41598-019-39525-3.

38.

Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial.

Di Cosimo S, Appierto V, Pizzamiglio S, Tiberio P, Iorio MV, Hilbers F, de Azambuja E, de la Peña L, Izquierdo M, Huober J, Baselga J, Piccart M, de Braud FG, Apolone G, Verderio P, Daidone MG.

Clin Cancer Res. 2019 Jul 1;25(13):3887-3895. doi: 10.1158/1078-0432.CCR-18-2507. Epub 2019 Feb 27.

PMID:
30814109
39.

Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study.

Mariani G, Galli G, Cavalieri S, Valagussa P, Bianchi GV, Capri G, Cresta S, Ferrari L, Damian S, Duca M, de Braud F, Moliterni A.

Breast J. 2019 Mar;25(2):237-242. doi: 10.1111/tbj.13197. Epub 2019 Feb 27.

40.

Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies.

Cona MS, Lecchi M, Cresta S, Damian S, Del Vecchio M, Necchi A, Poggi MM, Raggi D, Randon G, Ratta R, Signorelli D, Vernieri C, de Braud F, Verderio P, Di Nicola M.

Cancers (Basel). 2019 Feb 14;11(2). pii: E223. doi: 10.3390/cancers11020223.

41.

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients.

Del Re M, Cinieri S, Michelucci A, Salvadori S, Loupakis F, Schirripa M, Cremolini C, Crucitta S, Barbara C, Di Leo A, Latiano TP, Pietrantonio F, Di Donato S, Simi P, Passardi A, De Braud F, Altavilla G, Zamagni C, Bordonaro R, Butera A, Maiello E, Pinto C, Falcone A, Mazzotti V, Morganti R, Danesi R.

Pharmacogenomics J. 2019 Feb 6. doi: 10.1038/s41397-019-0077-1. [Epub ahead of print]

42.

Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?

Nichetti F, Falvella FS, Miceli R, Cheli S, Gaetano R, Fucà G, Infante G, Martinetti A, Antoniotti C, Falcone A, Di Bartolomeo M, Cremolini C, de Braud F, Pietrantonio F.

Pharmacogenomics J. 2019 Oct;19(5):465-472. doi: 10.1038/s41397-019-0078-0. Epub 2019 Feb 4.

PMID:
30713338
43.

Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles.

Vernieri C, Prisciandaro M, Milano M, Cona MS, Maggi C, Brambilla M, Mennitto A, Fabbroni C, Farè E, Cresta S, Celio L, Mariani G, Bianchi G, Capri G, de Braud F.

Clin Breast Cancer. 2019 Apr;19(2):e306-e318. doi: 10.1016/j.clbc.2018.12.004. Epub 2018 Dec 12.

PMID:
30635175
44.

MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review.

Lo Russo G, Tessari A, Capece M, Galli G, de Braud F, Garassino MC, Palmieri D.

Front Oncol. 2018 Dec 21;8:650. doi: 10.3389/fonc.2018.00650. eCollection 2018. Review.

45.

Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial.

Vernieri C, Signorelli D, Galli G, Ganzinelli M, Moro M, Fabbri A, Tamborini E, Marabese M, Caiola E, Broggini M, Hollander L, Gallucci R, Vandoni G, Gavazzi C, Triulzi T, Colombo MP, Rizzo AM, Corsetto PA, Pruneri G, de Braud F, Sozzi G, Torri V, Garassino MC.

Clin Lung Cancer. 2019 May;20(3):e413-e417. doi: 10.1016/j.cllc.2018.12.011. Epub 2018 Dec 19.

PMID:
30617039
46.

Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.

Modest DP, Rivera F, Bachet JB, de Braud F, Pietrantonio F, Koukakis R, Demonty G, Douillard JY.

Int J Cancer. 2019 Jul 15;145(2):576-585. doi: 10.1002/ijc.32110. Epub 2019 Jan 24.

47.

Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.

Schwartz S, Szeto C, Tian Y, Cecchi F, Corallo S, Calegari MA, Di Bartolomeo M, Morano F, Raimondi A, Fucà G, Martinetti A, De Pascalis I, Martini M, Belfiore A, Milione M, Orlandi A, Barault L, Barone C, de Braud F, Di Nicolantonio F, Benz S, Hembrough T, Pietrantonio F.

Eur J Cancer. 2019 Jan;107:164-174. doi: 10.1016/j.ejca.2018.11.016. Epub 2018 Dec 19.

PMID:
30579113
48.

Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases.

Pietrantonio F, Cotsoglou C, Fucà G, Lo Vullo S, Nichetti F, Milione M, Coppa J, Vaiani M, Alessi A, Prisciandaro M, Droz-Dit Busset M, Morano F, Corallo S, Lazzati S, Antista M, Mennitto A, Randon G, Raimondi A, Belfiore A, Padovano B, Perrone F, Mariani L, Di Bartolomeo M, de Braud F, Mazzaferro V.

Clin Colorectal Cancer. 2019 Mar;18(1):34-43.e6. doi: 10.1016/j.clcc.2018.11.004. Epub 2018 Nov 24.

PMID:
30558859
49.

Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.

Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, Randon G, De Braud F, Del Vecchio M.

J Cancer Res Clin Oncol. 2019 Feb;145(2):511-521. doi: 10.1007/s00432-018-2819-x. Epub 2018 Dec 11.

PMID:
30539281
50.

Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experience.

Cimminiello C, Indini A, Di Guardo L, Prisciandaro M, Randon G, Tolomio E, De Braud F, Del Vecchio M.

Melanoma Res. 2019 Jun;29(3):289-294. doi: 10.1097/CMR.0000000000000539.

PMID:
30520799

Supplemental Content

Loading ...
Support Center